Animal Health and Oncology Pivots Offer Long-Term Value in Healthcare Sector

While the broader healthcare sector has lagged behind general equities in recent years, specific opportunities in animal health and oncology are emerging as attractive long-term plays. Analysts suggest that companies pivoting their core strategies or expanding into underserved niches are best positioned for a recovery. Zoetis is highlighted as a strong candidate due to its dominance in animal health. Despite facing competition for its Apoquel product, the company is launching Portela and Lenivia, new long-acting osteoarthritis pain medicines for cats and dogs that require administration only every three months. Beyond product growth, Zoetis remains a top choice for income investors, having increased its dividend payouts by 458% over the last decade. BioNTech is similarly positioned for a rebound as it shifts focus away from the volatile coronavirus vaccine market. The company is aggressively pursuing oncology, with more than 25 phase 2 or phase 3 clinical trials currently underway. A key highlight is BNT327, a bispecific antibody developed in partnership with Bristol Myers Squibb, which the company believes could establish new standards of care across multiple indications. In contrast, Intellia Therapeutics is viewed with caution. Although the company is advancing its gene-editing platform with candidates like lonvo-z and nex-z, the latter faced a significant regulatory roadblock. Clinical trials for nex-z were placed on hold last year following the death of a patient and suspected adverse reactions, introducing substantial risk to the company's near-term outlook.